Takeda’s Alunbrig (brigatinib) Receives the US FDA’s Priority Review to Treat ALK + Metastatic Non-Small Cell Lung Cancer

 Takeda’s Alunbrig (brigatinib) Receives the US FDA’s Priority Review to Treat ALK + Metastatic Non-Small Cell Lung Cancer

Takeda’s Alunbrig (brigatinib) Receives the US FDA’s Priority Review to Treat ALK + Metastatic Non-Small Cell Lung Cancer

Shots:

  • The US FDA has granted PR to Takeda’s sNDA for the expanded use of Alunbrig (brigatinib) as 1L treatment for patients with ALK+ metastatic NSCLC detected by FDA-approved test
  • The sNDA is based on P-III ALTA-1L study assessing the Alunbrig (180mg qd with 7days preparatory phase to 90mg qd) vs crizotinib (bid) in 275 patients with LA/m-NSCLC, prior not treated with ALK inhibitor. The study resulted in meeting its 1EPs i.e, superiority in PFS
  • Alunbrig is a news generation ITK inhibitor targeting genetic alterations in ALK with its anticipated PDUFA date as Jun 23, 2020

Click here ­to­ read full press release/ article | Ref: Business wire  | Image: Takeda

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post